Company intelligence / Profile preview
Meitheal Pharmaceuticals
Chicago, Illinois, United Statesmeithealpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Meitheal has successfully launched multiple generic injectable medications including liraglutide injection recently approved by the FDA to address shortages[7]. They have ongoing clinical trials for biologic therapies including monoclonals and insulin biosimilars with plans to expand their portfolio significantly by end of year[1][3][6].
- Therapeutic areas
- ImmunologyEndocrinologyWomen's HealthOncologyInfectious Diseases
- Modalities
- Small moleculesBiosimilarsBiologicsInjectable generics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Strategic global partnerships with FDA-approved manufacturers/R&D partners across Europe, India, China[1]Licensing agreement for YUSIMRY® adalimumab biosimilar from Coherus BioSciences[6]Partnership with Premier on COVID‑19 research[1]
Beyond the preview
Go deeper on Meitheal Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meitheal Pharmaceuticals.